Addanki P. Kumar

531 total citations
10 papers, 432 citations indexed

About

Addanki P. Kumar is a scholar working on Molecular Biology, Cancer Research and Pharmacology. According to data from OpenAlex, Addanki P. Kumar has authored 10 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Cancer Research and 2 papers in Pharmacology. Recurrent topics in Addanki P. Kumar's work include Autophagy in Disease and Therapy (2 papers), Berberine and alkaloids research (2 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). Addanki P. Kumar is often cited by papers focused on Autophagy in Disease and Therapy (2 papers), Berberine and alkaloids research (2 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). Addanki P. Kumar collaborates with scholars based in United States. Addanki P. Kumar's co-authors include Rita Ghosh, Peng Meng, Thomas J. Slaga, Dinesh Thapa, Roble Bedolla, Robert L. Reddick, William L. Alworth, Natasha Kyprianou, Shylesh Bhaskaran and Guiming Li and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Carcinogenesis.

In The Last Decade

Addanki P. Kumar

10 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Addanki P. Kumar United States 9 265 87 69 66 49 10 432
Anna Klimaszewska‐Wiśniewska Poland 13 297 1.1× 75 0.9× 77 1.1× 62 0.9× 44 0.9× 41 522
Marta Hałas‐Wiśniewska Poland 11 231 0.9× 60 0.7× 76 1.1× 75 1.1× 41 0.8× 32 466
Robert Kleszcz Poland 15 356 1.3× 119 1.4× 94 1.4× 67 1.0× 37 0.8× 39 590
Vijay S. Thakur United States 11 342 1.3× 85 1.0× 102 1.5× 37 0.6× 126 2.6× 13 575
Linette Castillo‐Pichardo Puerto Rico 10 467 1.8× 103 1.2× 131 1.9× 47 0.7× 85 1.7× 19 753
Yi‐Ting Hsi Taiwan 13 283 1.1× 118 1.4× 50 0.7× 70 1.1× 39 0.8× 15 480
Mayrel Palestino Domínguez Mexico 9 201 0.8× 81 0.9× 99 1.4× 26 0.4× 36 0.7× 13 439
Srinivas Reddy Boreddy United States 7 353 1.3× 97 1.1× 80 1.2× 23 0.3× 42 0.9× 11 521
Yang Ho Park South Korea 11 242 0.9× 81 0.9× 97 1.4× 74 1.1× 51 1.0× 16 381
Sepideh Mirzaei Iran 10 338 1.3× 148 1.7× 102 1.5× 30 0.5× 72 1.5× 27 583

Countries citing papers authored by Addanki P. Kumar

Since Specialization
Citations

This map shows the geographic impact of Addanki P. Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Addanki P. Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Addanki P. Kumar more than expected).

Fields of papers citing papers by Addanki P. Kumar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Addanki P. Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Addanki P. Kumar. The network helps show where Addanki P. Kumar may publish in the future.

Co-authorship network of co-authors of Addanki P. Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Addanki P. Kumar. A scholar is included among the top collaborators of Addanki P. Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Addanki P. Kumar. Addanki P. Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Patel, Darpan I., et al.. (2015). Extracting the Benefit of Nexrutine® for Cancer Prevention. Current Pharmacology Reports. 1(6). 365–372. 14 indexed citations
2.
Meng, Peng, et al.. (2015). Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget. 6(9). 7195–7208. 82 indexed citations
3.
Thapa, Dinesh, Peng Meng, Roble Bedolla, et al.. (2014). NQO1 Suppresses NF-κB–p300 Interaction to Regulate Inflammatory Mediators Associated with Prostate Tumorigenesis. Cancer Research. 74(19). 5644–5655. 45 indexed citations
4.
Gong, Jingjing, et al.. (2013). FLIP: Molecular switch between apoptosis and necroptosis. Molecular Carcinogenesis. 53(9). 675–685. 17 indexed citations
5.
Li, Guiming, Roble Bedolla, Dinesh Thapa, et al.. (2012). Dietary Resveratrol Prevents Development of High-Grade Prostatic Intraepithelial Neoplastic Lesions: Involvement of SIRT1/S6K Axis. Cancer Prevention Research. 6(1). 27–39. 56 indexed citations
6.
Ghosh, Rita, et al.. (2009). Abstract #1: E2F2 in eugenol-induced inhibitory activities in malignant melanoma. Cancer Research. 69. 1–1. 4 indexed citations
7.
Bhaskaran, Shylesh, et al.. (2006). Akt- and CREB-Mediated Prostate Cancer Cell Proliferation Inhibition by Nexrutine, a Phellodendron amurense Extract. Neoplasia. 8(6). 523–533. 56 indexed citations
8.
Wisniewski, Hans‐Georg, M. Scott Lucia, Thomas J. Slaga, et al.. (2006). 2-Methoxyestradiol Inhibits Prostate Tumor Development in Transgenic Adenocarcinoma of Mouse Prostate: Role of Tumor Necrosis Factor-α–Stimulated Gene 6. Clinical Cancer Research. 12(3). 980–988. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026